The world's first human trial testing whether a drug can make a person's cells younger has begun, setting up a reality check for one of longevity research's most promising theories. The early-stage clinical trial will signal whether "cellular reprogramming" can be performed safely in humans, a prerequisite for any future claim that a treatment can slow or even reverse biological aging.
Attempts to prolong the human lifespan span everything from diet and exercise to unproven infusions of young donor blood plasma. The former is backed by decades of science; the latter has drawn two FDA warnings stating such treatments lack evidence of clinical benefit. Between these extremes lies a scientifically grounded middle ground centered on the idea that aging is a biological process that can be altered therapeutically.
"The field has two big components," one researcher noted. "There's some very serious science going on where things are very promising." The trial focuses on cellular reprogramming, a technique that aims to reset cells to a more youthful state by activating specific genes.
If successful, the approach could open the door to therapies that target aging itself rather than individual age-related diseases. But the field also risks being undermined by expensive quackery that erodes public trust in legitimate science.
Skeptics caution that even a safe trial does not guarantee effectiveness against aging in humans. Regulatory hurdles and the need for long-term data remain significant barriers before any clinical application.